Orsense - Non-Invasive Technologues

Please choose your location:

Orsense - non-invasive technologies

News & Events > Press Releases

OrSense's Non-Invasive Hemoglobin Measurement System for Pre-Donation Screening of Anemia Delivers Superior Clinical Value Compared to Current Methods

Oct. 19, 2011

Nes Ziona, Israel, October 20, 2011 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today that 3 poster presentations on the clinical value of its NBM 200 non-invasive hemoglobin (Hb) monitor for pre-donation screening of anemia will be presented at the AABB Annual Meeting & CTTXPO 2011, in San Diego, California, to be held on October 22-25, 2011. The findings indicate that Hb measurements using OrSense's NBM 200 are as accurate as measurements with currently available invasive devices. In addition, non-invasive measurements hold major advantages over current screening methods, such as the prevention of pain and potential transmission of infectious diseases to donors and caregivers, and the reduced need for trained personnel.

The following poster presentations will be presented:

Comparison Among a New Non-Invasive Hemoglobin Measurement System, Capillary Blood Azidemetahemoglobin Test and Red Blood Cell Count for Pre-Donation Screening. Belardinelli et al. Immunohematology and Transfusion Medicine, S.Orsola-Malpighi Hospital, Bologna, Italy.

Evaluation of a New Non-Invasive Hemoglobin Monitor as a Pre-Donation Application. Castro et al. Centro de Transfusión de Cruz Roja Española en Madrid, Spain.

Evaluation of a Non-Invasive Hemoglobin Estimation Method for Pre-Donation Screening in Blood Donors at a Tertiary Care Hospital Blood Bank in India – Verma; Dept. of Transfusion Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, India.

About OrSense's NBM 200 Non-Invasive Hemoglobin Screening System

Hemoglobin (Hb) measurements allow the detection of anemia and hemorrhage, and are widely used by hospital wards such as operating rooms, ICU, emergency and delivery rooms as well as in outpatient clinics and women’s and children’s health care facilities. In blood donation centers, a pre-donation Hb measurement of blood donors is required by most countries to protect anemic donors, and to ensure adequate Hb content of blood units. The determination of Hb levels of prospective blood donors is usually performed using capillary blood obtained by finger pricking, rendering current Hb screening methods invasive, painful, time consuming and labor intensive. Non-invasive measurement of Hb has many advantages including the prevention of pain and potential transmission of infectious diseases and the reduced need for trained personnel. NBM 200 offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. OrSense's portable non-invasive device operates via a ring-shaped sensor that is fitted on the donor's finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the donor's blood constituents, while greatly improving the donor's comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

About OrSense

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 40 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company's FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense's s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. The Company's CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s corporate website at www.orsense.com.

Press Contact:
Tsipi Haitovsky
Media Liaison
OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com

Press Releases Archive